Related Experiment Videos
Pemetrexed in gastric cancer
Alberto Sobrero1, Francesco Caprioni, Giuseppe Fornarini
1Divisione di Oncologia Medica Ospedale San Martino, Genova, Italy. alberto.sobrero@hsanmartino.liguria.it
Oncology (Williston Park, N.Y.)
|January 20, 2005
Summary
Gastric cancer presents a significant challenge with poor prognosis. Research is exploring novel chemotherapy agents and targeted therapies to improve survival rates and treatment effectiveness for advanced cases.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Gastric cancer poses a major clinical challenge with limited survival rates, especially in advanced stages.
- Current treatments, including surgery, offer palliative benefits but often fall short for advanced disease.
- Treatment advancements are crucial for improving patient outcomes.
Purpose of the Study:
- To review the evolution of treatment strategies for gastric cancer.
- To highlight the role of newer chemotherapy agents and targeted therapies.
- To discuss the potential impact of ongoing clinical trials and molecular research.
Main Methods:
- Review of current standard regimens and novel chemotherapy agents.
- Inclusion of oral fluoropyrimidines, taxanes, camptothecins, novel platinums (e.g., oxaliplatin), and antifolates (e.g., pemetrexed).
- Consideration of ongoing clinical trials and molecular research in gastric cancer pathogenesis.
Main Results:
- Improved response rates observed with newer chemotherapy agents.
- Development of standard regimens incorporating novel drugs like oxaliplatin and pemetrexed.
- Ongoing trials focus on enhancing survival and safety profiles.
Conclusions:
- Newer chemotherapy agents and targeted therapies show promise for gastric cancer treatment.
- Molecular research is vital for understanding disease pathogenesis and developing effective targeted treatments.
- Future treatment strategies may evolve from ongoing trial data and molecular insights, potentially improving patient survival and palliation.